Search research articles
Contact Us
Filters
Showing results (61-70 of 72) with videos related to
Page
of 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 21, 2023
Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials
J M Versluis, A M Menzies, K Sikorska, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 26, 2022
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study
Leonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
Data in Brief
|
November 25, 2022
Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis
Leonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
The Journal of Experimental Medicine
|
March 15, 2023
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
Irene L M Reijers, Disha Rao, Judith M Versluis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 27, 2024
Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo
Irene L M Reijers, Alexander M Menzies, Marta Lopez-Yurda, et al.
Nature Medicine
|
September 22, 2022
Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome
Rebecca C Simpson, Erin R Shanahan, Marcel Batten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2022
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma
Inês Pires da Silva, Tasnia Ahmed, Jennifer L McQuade, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 10, 2021
The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis
Judith M Versluis, Anne M Hendriks, Alison M Weppler, et al.
Nature Medicine
|
February 9, 2021
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
E A Rozeman, E P Hoefsmit, I L M Reijers, et al.
Journal for Immunotherapy of Cancer
|
July 6, 2022
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
Prachi Bhave, Tasnia Ahmed, Serigne N Lo, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 72) with videos related to
Sort By:
Page
of 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 21, 2023
Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials
J M Versluis, A M Menzies, K Sikorska, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 26, 2022
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study
Leonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
Data in Brief
|
November 25, 2022
Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis
Leonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
The Journal of Experimental Medicine
|
March 15, 2023
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
Irene L M Reijers, Disha Rao, Judith M Versluis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 27, 2024
Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo
Irene L M Reijers, Alexander M Menzies, Marta Lopez-Yurda, et al.
Nature Medicine
|
September 22, 2022
Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome
Rebecca C Simpson, Erin R Shanahan, Marcel Batten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2022
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma
Inês Pires da Silva, Tasnia Ahmed, Jennifer L McQuade, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 10, 2021
The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis
Judith M Versluis, Anne M Hendriks, Alison M Weppler, et al.
Nature Medicine
|
February 9, 2021
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
E A Rozeman, E P Hoefsmit, I L M Reijers, et al.
Journal for Immunotherapy of Cancer
|
July 6, 2022
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
Prachi Bhave, Tasnia Ahmed, Serigne N Lo, et al.
Page
of 8